Literature DB >> 201665

Evaluation of anti-complement immunofluorescence test in cytomegalovirus infection.

N Rao, D T Waruszewski, J A Armstrong, R W Atchison, M Ho.   

Abstract

The anti-complement immunofluorescence (ACIF) technique was evaluated for the diagnosis of human cytomegalovirus (CMV) infection in a group of sera derived from renal transplant recipients and donors by comparing it with the indirect immunofluorescence (FA) and complement fixation (CF) TESTS. The ACIF and FA tests yielded similar results. However, the ACIF test had a distinct advantage over the indirect FA test, since it eliminated the nonspecific cytoplasmic staining that may result in false positive readings in inexperienced hands. Both the indirect FA and ACIF tests were more sensitive than the CF test. In primary CMV infection, the FA and ACIF antibodies appeared earlier and had significantly higher titer than corresponding CF titers. This difference in titers was not seen in seropositive individuals who lacked overt infection. Our previously reported correlation between the seropositivity of the donor and CMV infection in seronegative recipients has been confirmed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 201665      PMCID: PMC274836          DOI: 10.1128/jcm.6.6.633-638.1977

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Virologic and clinical observations on cytomegalic inclusion disease.

Authors:  T H WELLER; J B HANSHAW
Journal:  N Engl J Med       Date:  1962-06-14       Impact factor: 91.245

2.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

3.  Studies on the complement-fixing antigens of poliomyelitis. III. Intracellular development of antigen.

Authors:  Y HINUMA; K HUMMELER
Journal:  J Immunol       Date:  1961-10       Impact factor: 5.422

4.  Evaluation of the complement method of fluorescent antibody technique with myxoviruses.

Authors:  Y HINUMA; R OHTA; T MIYAMOTO; N ISHIDA
Journal:  J Immunol       Date:  1962-07       Impact factor: 5.422

5.  Staining of complement and modification of fluorescent antibody procedures.

Authors:  R A GOLDWASSER; C C SHEPARD
Journal:  J Immunol       Date:  1958-02       Impact factor: 5.422

6.  The use of spiral loops in serological and virological micro-methods.

Authors:  G TAKATSY
Journal:  Acta Microbiol Acad Sci Hung       Date:  1955

7.  Comparative activity of immunofluorescent antibody and complement-fixing antibody in cytomegalovirus infection.

Authors:  R F Betts; S D George; R B Rundell; R B Freeman; R G Douglas
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

8.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

9.  Evidence for early nuclear antigens in cytomegalovirus-infected cells.

Authors:  L Geder
Journal:  J Gen Virol       Date:  1976-08       Impact factor: 3.891

10.  Congenital cytomegalovirus infection.

Authors:  S Stagno; D W Reynolds; E S Huang; S D Thames; R J Smith; C A Alford
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

View more
  10 in total

1.  Detection of human T-cell lymphotropic virus type III-related antigens and anti-human T-cell lymphotropic virus type III antibodies by anticomplementary immunofluorescence.

Authors:  R S Blumberg; E G Sandstrom; T J Paradis; D N Neumeyer; M G Sarngadharan; K L Hartshorn; R E Byington; M S Hirsch; R T Schooley
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

2.  Evaluation of the anticomplement immunofluorescence test for detection of antibody to varicella-zoster virus.

Authors:  C M Preissner; S P Steinberg; A A Gershon; T F Smith
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

Review 3.  Assessment of human cytomegalovirus antibody detection techniques.

Authors:  F Horodniceanu; S Michelson
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

4.  Virus replication and localization of varicella-zoster virus antigens in human embryonic fibroblast cells infected with cell-free virus.

Authors:  K Yamanishi; Y Matsunaga; T Ogino; M Takahashi; A Takamizawa
Journal:  Infect Immun       Date:  1980-05       Impact factor: 3.441

5.  OKT3 and viral disease in pediatric liver transplant recipients.

Authors:  James S Bowman; Michael Green; Velma P Scantlebury; Saturo Todo; Andreas Tzakis; Shunzaburo Iwatsuki; Laura Douglas; Thomas E Starzl
Journal:  Clin Transplant       Date:  1991-08       Impact factor: 2.863

6.  Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation.

Authors:  M K Breinig; B Zitelli; T E Starzl; M Ho
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

7.  T-cell populations in liver and renal transplant recipients with infectious esophagitis.

Authors:  D E Brouillette; J Alexander; Y K Yoo; M C Chien; R E Tarter; J Gavaler; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

8.  Infectious esophagitis following liver and renal transplantation.

Authors:  J A Alexander; D E Brouillette; M C Chien; Y K Yoo; R E Tarter; J S Gavaler; D H Van Thiel
Journal:  Dig Dis Sci       Date:  1988-09       Impact factor: 3.199

9.  Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies.

Authors:  N Singh; J S Dummer; S Kusne; M K Breinig; J A Armstrong; L Makowka; T E Starzl; M Ho
Journal:  J Infect Dis       Date:  1988-07       Impact factor: 5.226

10.  Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection.

Authors:  M Ho; G Miller; R W Atchison; M K Breinig; J S Dummer; W Andiman; T E Starzl; R Eastman; B P Griffith; R L Hardesty
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.